Insera Therapeutics, Inc. Receives U.S. FDA 510(k) Clearance for the CLEAR™ Aspiration System Featuring Cyclical Aspiration
Why now
Thesis: Private medtech clearance, no public equity link
Catalyst to watch: Commercial launch or partnership news
Main risk: Adoption unproven post-clearance
Why it matters
FDA clearance is a milestone for a private device firm; no listed ticker is affected.
Details
FDA clearance marks a major milestone for Insera's digital aspiration system using cyclical aspiration. DALLAS, Sept. 28, 2026 /PRNewswire/ -- Insera Therapeutics, Inc., a medical device company focused on advancing cyclical aspiration for mechanical thrombectomy, announced that it has...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-28 16:00 UTC